Abstract #0017

Predictive Value of Myo-inositol Measured by MRSI during Anti-angiogenic Treatment in Recurrent Glioblastoma

Michael Wenke¹, Jorg Dietrich², Elizabeth Gerstner², Otto Rapalino³, Julian He³, Daniel Kim¹, Melanie Fu¹, Pratik Talati⁴, Mohamed El Abtah¹, Anna Vaynrub¹, Sharif Natheir¹, Mark Vangel³, Isabel Arrillaga-Romany², Forst Deborah², Yi-Fen Yen¹, Ovidiu Andronesi¹, Jayashree Kalpathy-Cramer¹, Tracy Batchelor⁵, Bruce Rosen¹, R. Gilberto Gonzalez³, and Eva-Maria Ratai¹

¹Radiology / Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United States, ²Neurology / Cancer Center, Massachusetts General Hospital, Boston, MA, United States, ³Radiology, Massachusetts General Hospital, Boston, MA, United States, ⁴Neurosurgery, Massachusetts General Hospital, Boston, MA, United States, ⁵Neurology, Brigham and Women's Hospital, Boston, MA, United States

Patients with recurrent glioblastoma (rGBM) are commonly treated with anti-angiogenic agents such as bevacizumab (BEV), but not all benefit from this therapy. We examined whether MR spectroscopic imaging (MRSI) of myo-inositol (mI) could distinguish short-term survivors from longer term survivors (>9 month). We scanned twenty-two rGBM patients with MRSI at baseline prior to bevacizumab-based therapy, as well as 1-2 days, 4 weeks, 6-8 weeks and 16 weeks after treatment. We found that low tumoral myo-inositol normalized by creatine (Cr) on the contralateral site (mI/c-Cr) prior to and during anti-angiogenic therapy is predictive of poor survival.

This abstract and the presentation materials are available to members only; a login is required.

Join Here